Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...
Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it ...
FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...
Indian CRDMOs form IPSO trade group to boost manufacturing, includes Syngene, Aragen, Piramal & Sai Life Sciences.
Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...
For the fourth year running, Endpoints News will highlight the biotech leaders who are paving the way for the LGBTQ+ ...
Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top ...
Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain ...
RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but ...
Repare Therapeutics cuts 75% of workforce and CMO Maria Koehler departs amid program pause. Multiple companies announce layoffs, funding deals, and trial updates.
Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...
An unusual legal battle over a biotech startup's IPO plans escalated to another level on Valentine's Day, according to two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results